Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS
NCT03465085 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2018-03-14
Summary
Background: Intra-alveolar clotting and alveolar collapse in ARDS is due to alveolar capillaries epithelial and leakage. Subsequently, collapse induces hypoxemia that is resistant to recruitment (RM). Heparin and Streptokinase may prevent or dissolve intra-alveolar fibrin clot respectively helping alveolar re-expansion. We examined and compared the effect of nebulizing Heparin versus Streptokinase on reversing this pathology.
Methods: Sixty severe ARDS (PaO2/FiO2\<100) patients and failure of RM, prone position (PP) and neuromuscular block (NMB) were partially randomised into Group (I): (n=20) received nebulized Heparin 10000 IU/4h. Group (II): (n=20) received nebulized Streptokinase 250,000 IU/4h. Group (III): (n=20) received conservative management. Randomization to either Heparin or Streptokinase groups was applied to patients whom guardian accepted participation, while those who declined participation were followed-up as a control. The primary outcome was the change in PaO2/FiO2; the secondary outcomes included the change in compliance, plateau pressure, ventilation-off days, coagulation and ICU mortality.
Conditions
- Acute Respiratory Distress Syndrome
- Severe Acute Respiratory Syndrome
Interventions
- DRUG
-
Unfractionated heparin
Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
- DRUG
-
Streptokinase
Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
Sponsors & Collaborators
-
Beni-Suef University
lead OTHER
Principal Investigators
-
Hatem Hatem Elmoutaz Mahmoud, MD · Beni-Suef University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 21 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-18
- Primary Completion
- 2018-01-30
- Completion
- 2018-01-30
More Related Trials
-
"Effects of Neuromuscular Blocking Agents on End Expiratory Lung Volume During Moderate-severe ARDS"
NCT04996394 ·Status: COMPLETED
-
Nebulised Rt-PA for ARDS Due to COVID-19
NCT04356833 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of ARDS With Instilled T3
NCT04115514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
NCT00624650 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)
NCT00796419 ·Status: TERMINATED ·Phase: PHASE3
-
Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research Network
NCT00281268 ·Status: COMPLETED ·Phase: PHASE3
-
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
NCT00000579 ·Status: COMPLETED ·Phase: PHASE3
-
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
NCT05241067 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS
NCT03567577 ·Status: COMPLETED ·Phase: PHASE2
-
Time Course Evolution of Cardiac Output
NCT03694717 ·Status: COMPLETED
-
Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath
NCT05707936 ·Status: UNKNOWN ·Phase: NA
-
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
NCT04609865 ·Status: TERMINATED ·Phase: PHASE3
-
KL₄Surfactant Treatment in Patients With ARDS
NCT00215553 ·Status: TERMINATED ·Phase: PHASE2
-
Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation
NCT03787732 ·Status: COMPLETED ·Phase: PHASE4
-
Furosemide Stress Test to Predict Successful Liberation From RRT
NCT05612490 ·Status: COMPLETED
-
Nebulized hypErtonic Saline for Better Prevention of mUcus pLug in Critical Adult Tracheostomized Patients
NCT03870646 ·Status: UNKNOWN ·Phase: PHASE3
-
Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance
NCT06111261 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Strong Albumin Solutions in Patients With Septic Shock
NCT05208242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
NCT03848507 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Fluid Resuscitation and Microcirculation
NCT01369524 ·Status: COMPLETED
-
Ultrasound and Clinical Approach for the Dynamic Assessment of Fluid Tolerance in the Intensive Care Unit
NCT06415916 ·Status: RECRUITING
-
Fluids in Sepsis and Septic Shock
NCT02748382 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
NCT05306392 ·Status: UNKNOWN ·Phase: NA
-
Advanced Reperfusion Strategies for Refractory Cardiac Arrest
NCT03880565 ·Status: TERMINATED ·Phase: NA
-
Effect of Fluid Deresuscitation With Central Venous Pressure Target 0-4 mmHg in Septic Shock Patients
NCT04156451 ·Status: COMPLETED ·Phase: NA